<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; pharmexcil</title>
	<atom:link href="http://www.tapanray.in/tag/pharmexcil/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Data Manipulation: Leapfrogging Dangerously Into Clinical Trial Domain</title>
		<link>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain</link>
		<comments>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/#comments</comments>
		<pubDate>Mon, 03 Aug 2015 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[700]]></category>
		<category><![CDATA[Aurobindo]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jugaad]]></category>
		<category><![CDATA[Leapfrog]]></category>
		<category><![CDATA[Leapfrogging]]></category>
		<category><![CDATA[lifesciences]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[Malpractice]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[quest]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigmarole]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6908</guid>
		<description><![CDATA[Over the last several years, repeated allegations of gross data manipulative practices, detected by global drug regulatory agencies, such as USFDA and MHRA, have shaken the Indian pharma exporting companies hard. This has been hurting the overall business performance of &#8230; <a href="http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective</title>
		<link>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective</link>
		<comments>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/#comments</comments>
		<pubDate>Mon, 29 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[alert]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Bureau]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global. world]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[production]]></category>
		<category><![CDATA[ramparts. red fort]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sell]]></category>
		<category><![CDATA[speech]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6039</guid>
		<description><![CDATA[In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in &#8230; <a href="http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
